Project Grant K08AI202375
Award Date 9/1/26
Completion Date 8/31/31
Dollars Obligated $164K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Seattle, WA 98109, USA
Similar Awards
- The National Institute of Allergy and Infectious Diseases awarded Fred Hutchinson Cancer Center $879,998 on July 15, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to investigate the role of mucosal regulatory T cells in modulating tissue-resident memory T cell responses to infection. The research defines the features, fate, mechanisms, and functional consequences of regulatory T cells (Treg) and tissue Treg in anti-viral tissue memory immune responses in mice and...
- The National Institute of Allergy and Infectious Diseases awarded Fred Hutchinson Cancer Center $191,376 on August 11, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to map escape mutations in respiratory syncytial virus fusion protein and monitor for antibody-resistant viral strains. The recipient will develop a deep mutational scanning platform to comprehensively measure the effects of all possible mutations on cell entry and neutralization by clinically...
- The National Institute of Allergy and Infectious Diseases awarded Seattle Children's Hospital (doing business as Seattle Children's Research Institute) $859,765 on July 3, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to investigate the role of ferroptosis in regulating host control of Mycobacterium tuberculosis infection. The research examines how ferroptosis—a form of programmed cell death mediated by iron and lipid peroxidation—affects macrophage response to...
- The National Institute of Allergy and Infectious Diseases awarded Fred Hutchinson Cancer Center $323,892 on April 2, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to support a five-year research training program in mathematical modeling of SARS-CoV-2 variant emergence from immunocompromised hosts. The award funds development of a suite of mathematical models to understand mechanisms facilitating generation of SARS-CoV-2 variants of concern during prolonged...
- The National Institute of Allergy and Infectious Diseases awarded $436,454 to Massachusetts General Hospital on February 6, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to investigate gastrointestinal tract-driven T cell reprogramming during acute graft-versus-host disease (AGVHD). The recipient will conduct research across three specific aims examining how the gastrointestinal tract drives systemic alloimmunity in patients after allogeneic hematopoietic cell...
- The National Institute of Allergy and Infectious Diseases awarded Fred Hutchinson Cancer Center $191,376 on September 1, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to define cellular correlates of protection across attenuated whole-sporozoite malaria vaccine platforms. The research compares cellular immune responses to three different attenuated whole-sporozoite vaccines in malaria-naive individuals and correlates these responses with protection following...
- The National Institute of Allergy and Infectious Diseases awarded Fred Hutchinson Cancer Center $220,000 on July 1, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to develop a dual germline-targeting immunization strategy eliciting broadly neutralizing antibodies against HIV-1. The research uses preclinical transgenic mouse models and data from an ongoing Phase 1 clinical trial (HVTN301) to optimize a prime-boost vaccination approach with the germline-targeting...
- The National Institute of Allergy and Infectious Diseases awarded Fred Hutchinson Cancer Center $867,869 on June 3, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to identify and validate small molecule metabolites in vaginal fluid as diagnostic biomarkers for bacterial vaginosis, trichomoniasis, and vulvovaginal candidiasis. The research addresses an unmet clinical need: current diagnostic approaches for vaginal discharge syndrome are either rapid and inexpensive...
- The National Institute of Allergy and Infectious Diseases awarded The Johns Hopkins University $794,774 on September 1, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to develop a multi-tissue organotypic culture model (OCM) that integrates gut, liver, and blood components to study graft-versus-host disease (GVHD) in hematopoietic stem cell transplant recipients, with emphasis on pediatric patients. The project will create patient-specific OCM platforms using...
- The National Institute of Allergy and Infectious Diseases awarded The Washington University $388,750 on May 15, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to conduct research on targeting VLDLR to prevent both graft-versus-host disease and leukemia relapse in allogeneic hematopoietic cell transplantation. The research uses genome-wide CRISPR/CAS9 screening and gene set enrichment analysis to investigate very-low-density lipoprotein receptor as a therapeutic...